AARD vs CLOV

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Sep 17, 2026

AARD

55.8
AI Score
VS
AARD Wins

CLOV

39.0
AI Score

Investment Advisor Scores

AARD

56score
Recommendation
HOLD

CLOV

39score
Recommendation
SELL

AI Analyst Insights

Detailed Metrics Comparison

Metric AARD CLOV Winner
Forward P/E 0 37.7358 Tie
PEG Ratio 0 0 Tie
Revenue Growth 0.0% 55.6% CLOV
Earnings Growth 0.0% 0.0% Tie
Tradestie Score 55.8/100 39.0/100 AARD
Profit Margin 0.0% -0.7% AARD
Beta 1.00 1.00 Tie
AI Recommendation HOLD SELL AARD

Relative Price Performance (Last 90 Days)

AARD 1M: -23.6% · 3M: +38.4% CLOV 1M: +6.8% · 3M: -7.7%

Current Technical Phase

AARD

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 42

RSI (14): 42.2 · Price: $5.15

CLOV

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 53

RSI (14): 53.1 · Price: $4.56

Fundamentals Snapshot

Metric AARD CLOV
Market Cap
Forward P/E -1.9 28.8
Trailing P/E
Revenue (TTM)
Revenue Growth 0.0% 0.6%
Gross Margin 0.2%
Operating Margin 0.0% 0.0%
EPS -2.91 -0.05
Dividend Yield

Frequently Asked Questions

Based on our detailed analysis, AARD is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.